Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5493334 | 0.89 | GAA (0.42) | ALDH1A1GAAMAPTNPSR1TSHR | |
| SCHEMBL14248383 | 0.81 | ALDH1A1 (0.41) | ALDH1A1GAAMAPTTSHRHTT | |
| SCHEMBL755859 | 0.81 | TRPA1 (0.39) | ALDH1A1GAAMAPTNPSR1TSHR | |
| SCHEMBL23530425 | 0.81 | TRPA1 (0.39) | ALDH1A1GAAMAPTNPSR1TSHR | |
| SCHEMBL29414123 | 0.81 | TRPA1 (0.39) | ALDH1A1GAAMAPTNPSR1TSHR | |
| SCHEMBL11399520 | 0.79 | HTT (0.36) | ALDH1A1HTT | |
| SCHEMBL8813613 | 0.79 | UGT2B7 (0.33) | HTT | |
| SCHEMBL30585215 | 0.77 | PTPN2 (0.43) | ALDH1A1GAAMAPTNPSR1TSHR | |
| SCHEMBL8514874 | 0.77 | PTPN2 (0.43) | ALDH1A1GAAMAPTNPSR1TSHR | |
| SCHEMBL9609154 | 0.77 | PTPN2 (0.43) | ALDH1A1GAAMAPTNPSR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3164396-B1 | CYCLOHEXEN-1-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2019-01-16 | — | — | EP | disclosed |
| US-9957254-B2 | Cyclohexen-1-yl-pyridin-2-yl-1h-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2018-05-01 | — | — | US | disclosed |
| US-9957254-B2 | Cyclohexen-1-yl-pyridin-2-yl-1h-pyrazole-4-carboxylic acid derivatives and the use thereof as soluble guanylate cyclase activators | NOVARTIS AG (CH) | 2018-05-01 | — | — | US | disclosed |
| US-20170197941-A1 | CYCLOHEXEN-1-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| US-20170197941-A1 | CYCLOHEXEN-1-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| US-20170197941-A1 | CYCLOHEXEN-1-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2017-07-13 | — | — | US | disclosed |
| EP-3164396-A1 | CYCLOHEXEN-1-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | Novartis AG (CH) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016001878-A1 | CYCLOHEXEN-1-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | NOVARTIS AG (CH) | 2016-01-07 | — | — | WO | disclosed |
| US-20090137557-A1 | Calcilytic Compounds | SMITHKLINE BEECHAM CORPORATION | 2009-05-28 | — | — | US | disclosed |
| CN-101360498-A | Calcilytic compounds | SMITHKLINE BEECHAM CORP (US) | 2009-02-04 | — | — | CN | disclosed |
| US-5376653-A | A protease enzyme inhibitor for treating degenerative diseases , respiratory system disorders, rheumatoid arthritis and pancreatitis | STERLING WINTHROP INC. (US) | 1994-12-27 | — | — | US | disclosed |
| US-5306818-A | Treating degenerative diseases such as emphysema, rheumatoid arthritis and pancreatitis | STERLING WINTHROP INC. (US) | 1994-04-26 | — | — | US | disclosed |
| US-5296496-A | Treating degenerative diseases | STERLING WINTHROP INC. (US) | 1994-03-22 | — | — | US | disclosed |
| US-5250696-A | Treatment of degenerative diseases | STERLING WINTHROP INC. (US) | 1993-10-05 | — | — | US | disclosed |
| EP-0550112-A1 | 2-Saccharinylmethyl aryl and aryloxy acetates useful as proteolytic enzyme inhibitors and pharmaceutical compositions contaning them | STERLING WINTHROP INC. (US) | 1993-07-07 | — | — | EP | disclosed |
| EP-0550111-A1 | 2-Saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and pharmaceutical compositions containing them | STERLING WINTHROP INC. (US) | 1993-07-07 | — | — | EP | disclosed |
| EP-0549073-A1 | Novel 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof | STERLING WINTHROP INC. (US) | 1993-06-30 | — | — | EP | disclosed |
| US-5187173-A | Degenerative diseases such as emphysema, rheumatoid arthritis, pancreatitis, cyctic fibrosis and skin disorders | STERLING WINTHROP INC. (US) | 1993-02-16 | — | — | US | disclosed |
| US-5128339-A | Emphysema, rheumatoid arthritis, pancreatitis | STERLING WINTHROP INC. (US) | 1992-07-07 | — | — | US | disclosed |
| EP-0483928-A1 | 2-Saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use | STERLING WINTHROP INC. (US) | 1992-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197941-A1 | CYCLOHEXEN-1-YL-PYRIDIN-2-YL-1H-PYRAZOLE-4-CARBOXYLIC ACID DERIVATIVES AND THE USE THEREOF AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS | GUCY1A1, GUCY1A2, GUCY1B2 | ALDH1A1 546/4885GAA 805/4885MAPT 3714/4885 |
| US-20090137557-A1 | Calcilytic Compounds | CALCR, SOST, CALCB | ALDH1A1 4674/4885GAA 399/4885MAPT 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.